Subscribe to Newsletter

February 2017 Issue of The Medicine Maker

Welcome to the February issue. Upfront investigates antibiotic pollution in the supply chain, a “pharmtastic” voyage, and the impact of cannabis legalization on pharma. In our cover feature, we speak with Martin Van Trieste and Mark Paxton from Rx-360 about how to better protect patients through supply chain security. NextGen explores checkpoint inhibitors, and in business, George Chressanthis explains what Donald Trump’s policies may mean for pharma. We also sit down with Catherine Bollard, President of the International Society for Cellular Therapy (ISCT).

Register to download
Register here to download any issue of The Medicine Maker for FREE.
Login
Forgot your password?
Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Articles featured in this issue

 Business & Regulation Business Practice

Do Not Go Gentle Into That Good Night

| Stephanie Vine

PhRMA and the ABPI showcase the industry’s good side and the science behind the logo.
Manufacture Standards & Regulation

Testing the Water

| James Strachan

Pharma is urged to tackle the problem of polluted waste water from manufacturing plants.
Discovery & Development Packaging

The Art of Science

| Stephanie Vine

An art gallery at Pharmapack showcased the artistic side of primary drug packaging
Business & Regulation Business Practice

Breaking with Tradition

| Joanna Cummings

What does the legalization of medical cannabis mean for conventional pharmaceuticals?
Discovery & Development Drug Delivery

Pharmtastic Voyage

| James Strachan

A microscopic submarine neutralizes gastric acid for fuel to deliver drugs to the stomach.
Business & Regulation Business Practice

Business-in-Brief

| James Strachan

A campaign to counter criticism and a first foray into biosimilars… What’s new in business?
Discovery & Development Business Practice

Marketing Myths

| Elliott Berger

Elliott Berger offers his top 10 marketing tips for contract manufacturing organizations.

Business & Regulation Business Practice

Pharma to the Rescue

| Danny Stepto

What better way to engage with patients than partnering with Marvel Custom Solutions?
Discovery & Development Drug Delivery

Why Encapsulation Is (or Should Be) King

| Stephen Brown

For modern medicines, I believe that liquid-filled encapsulation has the edge.
Manufacture Clinical Trials

The Human Challenge

| Adrian Wildfire

Human challenge studies could allow us to better predict vaccines' real-world efficacy.
Manufacture Ingredients

Global Vigilance

| Martin VanTrieste

Martin Van Trieste tells the emotional story behind the creation of Rx-360
Business & Regulation Ingredients

Meeting Mark Paxton

| Mark Paxton

Mark Paxton was appointed CEO of Rx-360 in 2015. Here, he discusses the journey so far
Business & Regulation

Chasing Checkpoints

| Frédéric Triebel

The industry is scrambling to find more about therapeutic modulation of checkpoint signals.
Manufacture Small Molecules

Bringing API Manufacturing into Focus: Lessons Learned with Brian Chekal

| Brian Chekal

Brian recollects his early interest in science and discusses the latest trends in API manufacturing.
Business & Regulation Biosimilars

Russian Revolution for Biosimilars

| Roman Ivanov

Could manufacturers based in Russia be well placed to develop cheaper biopharmaceuticals?
Business & Regulation Business Practice

Make US Pharma Great Again!?

| George A Chressanthis

Donald Trump has vowed to lower drug prices, but what about his policies in other areas?
Manufacture Advanced Medicine

Cell Therapy Virtuoso

| Catherine Bollard

Sitting Down With... Catherine Bollard, President of the ISCT.
Manufacture Bioprocessing - Upstream & Downstream

An Intense Focus on Perfusion

Continuous manufacturing technologies are seeing increased industry uptake, particularly perfusion systems and, increasingly, intensified perfusion.
Discovery & Development Formulation

Quality From the Ground Up

| Sponsored by Capsugel

Six Sigma has the potential to deliver real cost savings by improving productivity and reducing defects, but making the change is challenging.
Manufacture Bioprocessing - Single Use Systems

Globalization of Single Use

We track the rapid rise of single use systems – and explore their role in the biomanufacturing facility of the future

Other issues of 2017